Image-guided dosimetry-based alpha particle therapy for neuroblastoma. - significance: neuroblastoma is the most common pediatric cancer, accounting for 15% of cancer deaths, with a 5-YR survival of…

Ended Grant Awarded Last action

Award ID
R44CA268314
Recipient
Awarding agency
Obligated
$1,951,675

Award facts

Assistance listing
93.395 Cancer Treatment Research
Completion date
Originally
Place of performance
Iowa, USA

Award details come from USAspending.gov.

Transactions

Action Obligated Date
Amendment $0
Amendment $961,450
Original award $990,225

Quick answers

Who received award R44CA268314?

R44CA268314 was awarded to Viewpoint Molecular Targeting, Inc. by National Cancer Institute (National Institutes of Health) on August 4, 2022.

How much is award R44CA268314 worth?

$1,951,675 has been obligated on R44CA268314.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award